Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer

Podcast

Liliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.

As part of the Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, of Florida Cancer Specialists in Fort Myers, Florida, and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.

In the video series, Bustamante and Kim discussed the following:

To watch more videos in the CancerNetwork® Between the Lines™ series, visit cancernetwork.com/between-the-lines.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content